Figure 5
FW-04-806 inhibits the tumor growth of SKBR3 and MCF-7 tumor xenograft models. (A and B) SKBR3 and MCF-7 tumor xenograft nude mice were randomized into treatment groups (n = 6/group) and received FW-04-806 at doses of 50, 100, 200 mg/kg i.g., q3d (in a vehicle of 10% ethanol, 10% polyethylene glycol 400, and 10% Tween 80) or ADM at doses of 4 mg/kg i.p., q3d, until the day that the tumor sizes of the vehicle control groups reached approximately 1000 mm3. Tumors were weighed to evaluate the anticancer activity of FW-04-806. Data are presented as means ± SD (n = 6, P < 0.01). (C and D) Mouse body weight was measured twice a week. (E) HER2 expression in SKBR3 tumors. Picture a shows vehicle controls; picture b, c and d show 50, 100 and 200 mg/kg groups, respectively. (F) Tumor tissues excised from the SKBR3 xenograft mice were lysed; changes in the levels of in HER2, p-HER2, Raf-1, Akt, and p-Akt protein were tested. (G) Tumor tissues excised from the MCF-7 xenograft mice were lysed; western blot detected the changes in the levels of in Raf-1, Akt, and p-Akt protein expressions.